Company: KROS
Filing Date: 2025-11-05
Form Type: 10-Q
Source: 0001664710-25-000089
Chunk: 227

Company: Keros Therapeutics, Inc.
Filing Date: 2025-11-05
Form: 10-Q
Item: Item 1
Chunk 227
---
, net of underwriting discounts, commissions, and offering costs of $9,9434,025,000 — 151,057 — 151,057 Exercise of common stock options201,702 — 5,721 — 5,721 Stock-based compensation— — 8,070 — 8,070 Net income (loss)— — — (43,114)(43,114)As of March 31, 202436,067,786 $3 $878,484 $(424,540)$453,947 Issuance of common stock under the ATM agreement, net of commissions and offering costs of $16414,068 $— $474 $— $474 Exercise of common stock options87,704 $— 2,967 $— 2,967 Stock-based compensation— $— 8,785 $— 8,785 Net income (loss)— $— — (45,257)$(45,257)As of June 30, 202436,169,558 $3 $890,710 $(469,797)$420,916 Issuance of common stock under the ATM agreement, net of commissions and offering cost of $2,3773,045,762 1 155,049 — $155,050 Exercise of common stock options43,156 — 1,008 — 1,008 Stock-based compensation— — 8,817 — 8,817 Net income (loss)— — — (52,956)(52,956)As of September 30, 202439,258,476 $4 $1,055,584 $(522,753)$532,835 

See notes to condensed consolidated financial statements.

7

KEROS THERAPEUTICS, INC.

Condensed Consolidated Statements of Cash Flows 

(In thousands) 

(Unaudited)

NINE MONTHS ENDED SEPTEMBER 30,20252024CASH FLOWS FROM OPERATING ACTIVITIES:Net income (loss)$110,475 $(141,327)Adjustments to reconcile net income (loss) to net cash used in operating activities:Depreciation expense1,109 897 Gain on disposal of fixed asset(14)— Stock-based compensation expense21,391 25,672